Below you will find the answers to many commonly asked questions. If you do not find the answer to your questions here or elsewhere on our web site, please feel free to contact us today. We’ll be happy to answer them promptly!
Essentially, stem cells are progenitor cells which are capable of regeneration and differentiation into a wide range of specialized cell types. Once injected, stem cells follow inflammatory signals from damaged tissues and have multiple ways of repairing these damaged areas.
The mesenchymal stem cells (MSCs) we are using are considered to be multipotent (they can transform into different cell types but cannot form an organ) but not pluripotent.
They act via anti-inflammatory activity, immune modulating capacity, and the ability to stimulate regeneration. The lab we work with goes through a very high throughput screening process to find cells that we know have the best anti-inflammatory activity, the best immune modulating capacity, and the best ability to stimulate regeneration.
Currently, Insurance does not cover these procedures.
How much does this treatment cost?
Treatment cost depends on the type of treatment required and will be discussed with you following patient application and diagnosis. The cost of treatment includes the treatment itself plus advanced wellness adjunctive therapies to help your body heal faster. Fees for services start at $7,000.
How long does it take to see results?
Each treatment and patient is unique, and there is no guarantee of what results will be seen or how quickly they may be observed. Some patients have commented on changes during the course of their treatment, others have experienced improvement within 6-9 months.
Where do stem cells come from?
REGENCare utilizes adult stem cells derived from Human Umbilical Cord Tissue – a rich source of mesenchymal stem cells (MSCs).
Are the umbilical cord tissue-derived stem cells approved by the US FDA?
The stem cells we utilize are the only umbilical cord MSCs that have received an IND designation from the US FDA. These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient)
REGENCare has put together extensive research to support the safety of our therapies.